Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease

F. Stocchi, J. M. Rabey

Research output: Contribution to journalArticlepeer-review


Background: The LARGO study demonstrated that rasagiline 1mg/day as adjunct to levodopa significantly reduces OFF time to the same magnitude as adjunct entacapone. This substudy of LARGO aimed to assess the effect of rasagiline and entacapone on the motor symptoms of PD during the practically defined OFF state. Methods: LARGO was a randomized, double-blind, multicenter trial that assessed the efficacy and safety of rasagiline (1mg/day), entacapone (200mg with each levodopa dose), and placebo in 687 levodopa-treated PD patients with motor fluctuations. A substudy of LARGO measured UPDRS motor scores in the practically defined OFF state in 32 rasagiline, 36 entacapone, and 37 placebo patients. Results: Treatment with rasagiline produced a significant improvement over placebo of 5.64units in UPDRS motor OFF score (P=0.013 vs. placebo). By contrast, the effect of adjunct entacapone was not significant (P=0.14 vs. placebo). Whereas rasagiline also showed a trend in reducing the UPDRS-ADL OFF score (P=0.058 vs. placebo), no such trend was noted for entacapone (P=0.26 vs. placebo). Retrospective analysis, using the Bonferroni correction, of UPDRS motor subdomains further revealed that rasagiline, but not entacapone, significantly improved bradykinesia (P

Original languageEnglish
Pages (from-to)1373-1378
Number of pages6
JournalEuropean Journal of Neurology
Issue number12
Publication statusPublished - Dec 2011


  • Entacapone
  • Motor control
  • Parkinson's disease
  • Rasagiline

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease'. Together they form a unique fingerprint.

Cite this